Table 1 Recent completed or ongoing research experiments on CAR-T cell therapy for endocrine cancers
From: The potential of chimeric antigen receptor -T cell therapy for endocrine cancer
Target antigens | Receptor type (other specificity) | Type of cancer | Country of the study | Author | Year |
|---|---|---|---|---|---|
ERBB2 | chA21-ScFV-CD8a-CD28-CD3ζ | Ovarian cancer | China | Meili Sun | 2014 |
CD24 | ScFV-CD28−4−1BB-CD3ζ | Ovarian cancer | Germany | Rüdiger Klapdor | 2019 |
TAG72 | ScFV−4−1BB-CD3ζ | Ovarian cancer | USA | John P. Murad | 2018 |
EpCAM | ScFV-CD8a-CD8-CD28−4−1BB-CD3ζ | Ovarian cancer | China | Juan FU | 2020 |
MSLN | ScFV−4−1BB-CD3ζ | Ovarian cancer | China |  | 2021 |
TM4SF1 | ScFV-CD8-CD28−4−1BB-CD3ζ | Ovarian cancer | China | Yijie Shen | 2023 |
CLDN18.2 | ScFV-CD8a−4−1BB-CD3ζ | Pancreatic cancer | China | Changsong Qi | 2022 |
CEA | SCA431scFv-IgG1-CD4-CD28-CD3ζ | Pancreatic cancer | Germany | Markus Chmielewski | 2012 |
MUC1 | ScFV−4−1BB-CD3ζ | Pancreatic cancer | USA | Posey | 2016 |
Trop2 | 2F11scFv-CD8−4−1BB-CD3ζ | Pancreatic cancer | China | Hongjia Zhu | 2022 |
EGFR | Â | Pancreatic cancer | China | Yang Liu | 2020 |
SSEA−4 | ScFV-CD28-CD3ζ | Pancreatic cancer | China | Chih-Wei Lin | 2021 |
TSHR | ScFV-CD28−4−1BB-CD3ζ | Thyroid cancer | China | Hanning Li | 2021 |
ICAM−1 | ScFV-CD28−4−1BB-CD3ζ | Thyroid cancer | USA | Irene M. Min | 2017 |
GFRa4 | ScFV-CD137-CD3ζ | Thyroid cancer | USA | Vijay G. Bhoj | 2020 |